bioRxiv · 10.1101/657734
Mendelian Randomization Analysis Dissects the Relationship between NAFLD, T2D, and Obesity and Provides Implications to Precision Medicine
Abstract
BackgroundNon-alcoholic fatty liver disease (NAFLD) is epidemiologically correlated with both type 2 diabetes (T2D) and obesity. However, the causal inter-relationships among the three diseases have not been completely investigated.\n\nAimWe aim to explore the causal relationships among the three diseases.\n\nDesign and methodsWe performed a genome-wide association study (GWAS) on fatty liver disease in [~]400,000 UK BioBank samples. Using this data as well as the largest-to-date publicly available summary-level GWAS data, we performed a two-sample bidirectional Mendelian Randomization (MR) analysis. This analysis tested the causal inter-relationship between NAFLD, T2D, and obesity, as well as the association between genetically driven NAFLD (with two well-established SNPs at the PNPLA3 and TM6SF2 loci) and glycemic and lipidemic traits, respectively. Transgenic mice expressing the human PNPLA3 I148I (TghPNPLA3-I148I) and PNPLA3 I148M (TghPNPLA3-I148M) isoforms were used to further validate the causal effects.\n\nResultsWe found that genetically instrumented hepatic steatosis significantly increased the risk for T2D (OR=1.3, 95% CI: [1.2, 1.4], p=8.3e-14) but not the intermediate glycemic phenotypes at the Bonferroni-adjusted level of significance (p<0.002). There was a moderate, but significant causal association between genetically driven hepatic steatosis and decreased risk for BMI ({beta}=- 0.027 SD, 95%CI: [-0.043, -0.01], p=1.3e-4), but an increased risk for WHRadjBMI (Waist-Hip Ratio adjusted for BMI) ({beta}=0.039 SD, 95%CI: [0.023, 0.054], p=8.2e-7), as well as a decreased level for total cholesterol ({beta}=-0.084 SD, 95%CI [-0.13, -0.036], p=6.8e-4), but not triglycerides ({beta}=0.02 SD, 95%CI [-0.023, 0.062], p=0.36). The reverse MR analyses suggested that genetically driven T2D (OR=1.1, 95% CI: [1.0, 1.2], p=1.7e-3), BMI (OR=2.3, 95% CI: [2.0, 2.7], p=1.4e-25) and WHRadjBMI (OR=1.5, 95% CI: [1.3, 1.8], p=1.1e-6) causally increase the NAFLD risk. In the animal study, as compared to the TghPNPLA3-I148I controls, the TghPNPLA3-I148M mice developed higher fasting glucose level and reduced glucose clearance. Meanwhile, the TghPNPLA3-I148M mice demonstrated a reduced body weight, increased central to peripheral fat ratio, decreased circulating total cholesterol as compared to the TghPNPLA3-I148I controls.\n\nConclusionThis large-scale bidirectional MR study suggests that lifelong, genetically driven NAFLD is a causal risk factor for T2D (hence potentially a \"NAFLD-driven T2D\" subtype) and central obesity (or \"NAFLD-driven obesity\" subtype), but protects against overall obesity; while genetically driven T2D, obesity, and central obesity also causally increase the risk of NAFLD, hence a \"metabolic NAFLD\". This causal relationship revealed new insights into disease subtypes and provided novel hypotheses for precision treatment or prevention for the three diseases.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Liu, Z., Zhang, Y., Graham, S., Pique-Regi, R., Dong, X. C., Chen, Y. E., Willer, C., Liu, W.. 2019-06-07. Mendelian Randomization Analysis Dissects the Relationship between NAFLD, T2D, and Obesity and Provides Implications to Precision Medicine. https://doi.org/10.1101/657734
Cite the original work for its findings. Save a collection to share your selection of sources.